Noa G. Holtzman, M.D.
Dr. Holtzman's main research interests include hematopoietic stem cell transplantation (HSCT) for hematologic malignancies with a focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), graft-versus-host disease (GVHD), improving post-transplant outcomes, and cellular immunotherapy.
1) hematopoietic stem cell transplantation, 2) graft-versus-host disease, 3) hematologic malignancies, 4) myelodysplastic syndromes, 5) acute myeloid leukemia, 6) cellular therapy
Dr. Holtzman is involved in clinical research focused on improving post-HSCT outcomes for hematologic malignancy patients, including immunomodulatory strategies for prevention of post-HSCT relapse. She is active in clinical trials evaluating JAK inhibitors and other new agents for treatment of refractory chronic GVHD on the team led by Dr. Steven Pavletic. Dr. Holtzman is also involved in the implementation of several clinical trial protocols for treatment of MDS under the new NIH myeloid malignancies program.
Selected Recent Publications
Immune Effector Cell- Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes.Neuro Oncol. Epub ahead of print (Aug. 5), 2020. [ Journal Article ]
Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.Am J Hematol. Epub ahead of print (Jan. 5), 2020. [ Journal Article ]
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.Br J Haematol. 188(6): 881-887, 2020. [ Journal Article ]
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.Am J Hematol. 94(8): E216-E219, 2019. [ Journal Article ]
- Blood. 129(17): 2335-2336, 2017. [ Journal Article ]
Dr. Holtzman earned a B.A. in Biological Sciences from Cornell University in 2009 and received her M.D. from Jefferson Medical College in 2013. She then completed internal medicine residency training in 2016 and a fellowship in hematology/oncology with a sub-fellowship focus in bone marrow transplantation and cellular therapy in 2019 at the University of Maryland Medical Center. Dr. Holtzman is triple board-certified in internal medicine, hematology, and medical oncology.